Trybe Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ginkgo Bioworks
DNA
|
+$14.7M |
| 2 |
Marvell Technology
MRVL
|
+$6.56M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SRNG
Soaring Eagle Acquisition Corp. Class A Ordinary Share
SRNG
|
+$5.99M |
| 2 |
ARK Genomic Revolution ETF
ARKG
|
+$5.96M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 58.4% |
| 2 | Communication Services | 16.22% |
| 3 | Consumer Discretionary | 8.95% |
| 4 | Financials | 8.45% |
| 5 | Healthcare | 7.97% |
Similar funds
Trybe Capital Management's Q3 2021 Portfolio in Review
As of Q3 2021, Trybe Capital Management held 14 positions worth $176M, up 7.1% from $164M the previous quarter. Its ten largest holdings account for 91% of the portfolio.
Trybe Capital Management deployed $9.31M of net new capital in Q3 2021, opening 2 new positions. Its largest new stake was Ginkgo Bioworks: 30,200 shares worth $14M.
By sector, the portfolio is most concentrated in Technology at 58% of assets, up from 56% a quarter earlier, followed by Communication Services and Consumer Discretionary.
On the sell side, the most notable exit was Soaring Eagle Acquisition Corp. Class A Ordinary Share, an estimated $5.99M sold.
- Trybe Capital Management's largest Q3 2021 buy was Ginkgo Bioworks: 30,200 shares worth $14M.
- Trybe Capital Management fully exited Soaring Eagle Acquisition Corp. Class A Ordinary Share in Q3 2021, selling an estimated $5.99M.
- Trybe Capital Management's ten largest holdings make up 91% of its $176M portfolio in Q3 2021.
- Trybe Capital Management opened 2 new positions and closed 2 in Q3 2021.
- Trybe Capital Management's portfolio value rose 7.1% quarter-over-quarter to $176M.
Based on Trybe Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.